This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Briassouli, P. Articles by Linardopoulos, S. Search for Related Content PubMed PubMed Citation Articles by Briassouli, P. Articles by Linardopoulos, S.

Aurora-A Regulation of Nuclear Factor-B Signaling by Phosphorylation of IB

¹ The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom and ² Centre for Cancer Therapeutics, The Institute of Cancer Research, Cancer Research UK, Belmont, Surrey, United Kingdom

Requests for reprints: Spiros Linardopoulos, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United Kingdom. Phone: 44-207-153-5341; Fax: 44-207-153-5340; E-mail: spiros.linardopoulos{at}icr.ac.uk.

The Aurora-A/STK15 gene encodes a kinase that is frequently amplified in cancer. Overexpression of Aurora-A in mammalian cells leads to centrosome amplification, genetic instability, and transformation. In this study, we show that Aurora-A activates nuclear factor-B (NF-B) via IB phosphorylation. Inhibition of endogenous Aurora-A reduces tumor necrosis factor (TNF)–induced IB degradation. We analyzed primary human breast cancers, and 13.6% of samples showed Aurora-A gene amplification, all of which exhibited nuclear localization of NF-B. We propose that this subgroup of patients with breast cancer might benefit from inhibiting Aurora-A. We also show that down-regulation of NF-B via Aurora-A depletion can enhance cisplatin-dependent apoptosis. These data define a new role for Aurora-A in regulating IB that is critical for the activation of NF-B–directed gene expression and may be partially responsible for the oncogenic effect of Aurora-A when the gene is amplified and overexpressed in human tumors. [Cancer Res 2007;67(4):1689–95]

This article has been cited by other articles:

				X.-B. Wan, Z.-J. Long, M. Yan, J. Xu, L.-P. Xia, L. Liu, Y. Zhao, X.-F. Huang, X.-R. Wang, X.-F. Zhu, et al. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells Carcinogenesis, October 1, 2008; 29(10): 1930 - 1937. [Abstract] [Full Text] [PDF]

				D. F. Calvisi, F. Pinna, S. Ladu, R. Pellegrino, M. R. Muroni, M. M. Simile, M. Frau, M. L. Tomasi, M. R. De Miglio, M. A. Seddaiu, et al. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease Carcinogenesis, August 1, 2008; 29(8): 1639 - 1647. [Abstract] [Full Text] [PDF]

				X.-F. Huang, S.-K. Luo, J. Xu, J. Li, D.-R. Xu, L.-H. Wang, M. Yan, X.-R. Wang, X.-B. Wan, F.-M. Zheng, et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia Blood, March 1, 2008; 111(5): 2854 - 2865. [Abstract] [Full Text] [PDF]

				F. Chan, C. Sun, M. Perumal, Q.-D. Nguyen, V. Bavetsias, E. McDonald, V. Martins, N. E. Wilsher, F. I. Raynaud, M. Valenti, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity Mol. Cancer Ther., December 1, 2007; 6(12): 3147 - 3157. [Abstract] [Full Text] [PDF]

				J. T. Irelan, T. J. Murphy, P. D. DeJesus, H. Teo, D. Xu, M. A. Gomez-Ferreria, Y. Zhou, L. J. Miraglia, D. R. Rines, I. M. Verma, et al. A role for I{kappa}B kinase 2 in bipolar spindle assembly PNAS, October 23, 2007; 104(43): 16940 - 16945. [Abstract] [Full Text] [PDF]